Eli Lilly (LLY) Wins EMA Backing for Jaypirca in CLL

Eli Lilly (NYSE:LLY) announced that its drug Jaypirca (pirtobrutinib) received a positive opinion from the European Medicines Agency (EMA) for the treatment of chronic lymphocytic leukemia (CLL). The opinion recommends Jaypirca for use across all lines of therapy, potentially expanding its reach significantly in Europe.

Details of the Action

The CHMP of the EMA recommended approval of Jaypirca for adult patients with CLL who have received prior therapy. The opinion is based on data from the Phase 3 BRUIN CLL-321 trial, which demonstrated efficacy in patients who failed prior treatment.

Company's Position

Eli Lilly welcomes the positive opinion, viewing it as a key step toward providing a new treatment option for CLL patients in Europe. Although the company is best known recently for its GLP-1 portfolio in diabetes and obesity, oncology remains a core part of its business.

Precedents and Context

Jaypirca already received conditional approval in the EU for mantle cell lymphoma (MCL) in 2023. It is also approved in the US for both CLL and MCL. This latest positive opinion represents a potential expansion of its approved indications.

Potential Financial Impact

Eli Lilly has not disclosed a direct financial impact, but expanding Jaypirca's use could boost oncology revenues. Analysts estimate peak sales of Jaypirca at around $1.5 billion annually.